NCT00030368 Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors Status COMPLETED Phase PHASE1
NCT00028912 Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Status COMPLETED Phase PHASE1
NCT00028587 PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT00027898 Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT00027716 Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma Status COMPLETED Phase PHASE2
NCT00024011 PS-341 in Treating Patients With Metastatic Malignant Melanoma Status COMPLETED Phase PHASE2
NCT00023881 Bortezomib in Treating Patients With Chronic Myelogenous Leukemia Status TERMINATED Phase PHASE2
NCT00023855 PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT00023764 Bortezomib in Treating Patients With Lymphoproliferative Disorders Status COMPLETED Phase PHASE2
NCT00023712 Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Status COMPLETED Phase PHASE2
NCT00017199 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Status COMPLETED Phase PHASE2
NCT00011778 PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck Status COMPLETED Phase PHASE1
NCT00007878 Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery Status COMPLETED Phase PHASE1